Drilldown: Medicines

Atomoxetine (1) · Butorphanol (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Ethylmorphine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Levorphanol (1) · Meperidine (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Tapentadol (1)

None (5) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Strattera (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (15) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000013-QINU`"' (1)

None (15) · Adult: 15–60 mg every 4 hours as needed. (1) · Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks (1)

None (15) · Capsules 10, 18, 25, 40, 60, 80, 100 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (15) · 100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) (1) · 360 mg/day (1)

None (15) · Oral (1) · PO (only formulation marketed in the US). (1)

None (15) · 30–60 min (PO) (1) · ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks (1)

None (15) · 24 hours (once-daily or split BID dosing) (1) · 4–6 hours (1)

None (15) · 2.5–3 hours (1) · ~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"' (1)

None (15) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' (1)

None (15) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (15) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"' (1)